Member Value

Dexcom CGM empowers members, providing greater glucose awareness.

Greater Glucose Awareness Has Proven to Reduce Time in Hypoglycemia and Increase Time in Target.1

The Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System delivers up to 288 readings every 24 hours, empowering patients with continuous data and feedback. On average, Dexcom CGM users check their screen 29 times per day.2

 

 

Power of Rate of Change

CGM users adjust their insulin more frequently,3 and CGM rate-of-change (ROC) arrows were the dominant factor in insulin dose adjustment.4

Insulin Adjustments Based on Rate-of-Change Arrows

One arrow down

In a survey of CGM users, on average they reported:4

  • 50% reduction for a correction dose with single arrow down compared to when glucose is stable ((multiple daily injections (MDI))
  • 37% reduction for a correction dose with single arrow down compared to when glucose is stable (insulin pump)

Two arrows down

  • 52% reduction for a correction dose with two arrows down compared to when glucose is stable (MDI)
  • 38% reduction for a corrrection dose with two arrows down comapred to when glusoce is stable (insulin pump)

Two arrows up

  • 146% increase for a correction dose with two arrows up compared to when glucose is stable (MDI)
  • 138% increase for a correction dose with two arrows up compared to when glusocse is stable (insulin pump)

Benefits of Insulin Adjustment

Based on the information provided by CGM, users make frequent adjustments to the amount and timing of boluses as well as lower glucose targets, translating the information provided by CGM into actionable decisions that can contribute to A1C reductions and better overall glycemic control.5

 

Dexcom Makes Effective Diabetes Management an Easy Lifestyle Choice

The Dexcom G5 Mobile incorporates a lifestyle-friendly system design with an exceptional user experience for access to dynamic glucose data anywhere, anytime from a compatible smart device. 

With the Dexcom G5 Mobile App, members can view real-time glucose data and trends right on a smart device, with the option to share data with up to five loved ones ("Followers").

Followers can download the Dexcom Follow App to view their loved one's glucose activity from a smart device, providing members with added support when they need it.

Dexcom CLARITY®, Web-Based Diabetes Management Platform for Members and Providers

Dexcom CLARITY software is intended for use by both members and healthcare professionals to assist them in the review, analysis and evaluation of historical CGM data in support of effective diabetes management.

Dexcom CLARITY software and the Dexcom CLARITY Reports app captures continuous glucose monitoring data so patients and healthcare professionals can view glucose patterns, trends and statistics anytime, anywhere. The reports are available to download, print, email and export.

Dexcom G5 Mobile Quick Start Guide

View the Dexcom G5 Mobile Quick Start Guide.

Dexcom CLARITY Software

Learn more about Dexcom CLARITY software.

Dexcom CGM Products

Learn more about Dexcom CGM products.

 

For a list of compatible devices, visit dexcom.com/compatibility

The Dexcom Follow App is not included as part of the Dexcom G5 Mobile CGM System. Followers must download the Dexcom Follow App separately. Internet connectivity required to access Dexcom Follow. Followers should always confirm readings on the Dexcom G5 Mobile App or Receiver before making treatment decisions.

1

Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The diamond randomized clinical trial. JAMA. 2017;317(4):371-378. doi:10.1001/jama.2016.19975.

2

Dexcom internal data on file, 2016.

3

Battelino T, Conget I, Olsen B, et al. The use and e cacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155-3162 727-23.

4

Pettus J, Edelman S. Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring. Diabetes Technology & Therapeutics, Volume 18, Supplement 2, 2016.

5

Pettus J, Price DA, Edelman SV. How Patients with Type 1 Diabetes Translate Continuous Glucose Monitoring Data into Diabetes Management Decisions. Endocr Pract. 2015;:1-25.